Recent studies suggest that high expression of EIF4G1 is associated with poor prognosis of pancreatic ductal adenocarcinoma and prostate cancer and may serve as a novel prognostic biomarker [56, 57]. This evidence concerns the gene EIF4G1 and prostate carcinoma.